People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Paragon Biosciences Emalex Capital, Inc. | — | Pharmaceuticals | Series D+ | $376.8M | $5.5B | 2022 |
Jeffrey J. Aronin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey J. Aronin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Antonio Gracias | 1 | 15 |
| Patrick J. Morris | 1 | 8 |
| Darien J. Parhad | 1 | 7 |
| Antonio J. Gracias | 1 | 7 |
| Patrick Morris | 1 | 6 |
| Jeffrey Aronin | 1 | 6 |
| Timothy Cunniff | 1 | 5 |
| Darien Parhad | 1 | 4 |
| Ricky J. Sun | 1 | 2 |
| Jeffrey J. Dayno | 1 | 1 |
| Eric J. Messner | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.